NVAX

Business Context and Reporting Period

Company: NOVAVAX INC
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Business Overview: Novavax is a specialty pharmaceutical company focused on women's health and infectious diseases. Its primary asset is ESTRASORB, a topical estrogen replacement therapy for menopausal hot flushes. The company also markets a line of prescription pharmaceuticals and prenatal vitamins (Nestabs, Gynodiol, AVC) acquired through the 2000 purchase of Fielding Pharmaceutical Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 38% from 2001 to 2002. This was driven by a $4.5 million drop in product sales (due to generic competition for prenatal vitamins and declines in AVC/Gynodiol), a $1.7 million drop in contract research, and a $2.9 million drop in milestone/licensing fees.
• Increased Losses: Net loss more than doubled to $22.7 million. This was primarily due to the revenue decline and a $4.3 million increase in selling and marketing expenses in preparation for the anticipated ESTRASORB launch.
• Liquidity Deterioration: Cash reserves dropped from $20.0 million to $3.0 million due to $21.1 million in operating cash outflows and $9.7 million in capital expenditures for the new manufacturing facility.
• Debt Increase: Convertible notes payable to King Pharmaceuticals increased by $10.0 million to a total of $40.0 million.

Guidance, Outlook, and Risks

Regulatory Status and Outlook

The FDA completed its review of the ESTRASORB New Drug Application (NDA) in April 2002 but requested additional Chemistry, Manufacturing, and Controls (CMC) information. Novavax voluntarily withdrew the NDA and resubmitted it in September 2002; the FDA accepted it for review in November 2002. Management anticipates approval in 2003.

Capital Resources

Following a $16.6 million private equity placement in February 2003, management estimates cash resources will fund operations for the next 12 to 15 months. Without additional financing, the company may need to delay or reduce R&D programs.

Key Risks and Contingencies

• Regulatory Risk: No guarantee of FDA approval for ESTRASORB. Failure to secure approval would have a significant negative effect on the business.
• Market Risk: The estrogen replacement market is highly competitive (dominated by Wyeth's Premarin). The July 2002 Women's Health Initiative study negatively impacted the market for combination hormone therapies, though ESTRASORB is a single-agent product.
• Internal Control Failure: In October 2002, the company discovered a former employee embezzled approximately $450,000. $200,000 was recovered via insurance; the remainder is being pursued. This resulted in an expense charge in 2002.
• Related Party Transactions: The company provided promissory notes totaling ~$1.5 million to two directors for stock option exercises and guaranteed a $500,000 margin loan for a director.

Investor Verification Checklist

• ESTRASORB Approval Timeline: Verify the current status of the resubmitted NDA and any new FDA correspondence regarding the CMC issues.
• Cash Burn Rate: Confirm the actual cash runway post-February 2003 financing and the necessity for further capital raises in 2003.
• Product Sales Trends: Monitor the continued decline in legacy product sales (Nestabs, Gynodiol) due to generic competition.
• King Pharmaceuticals Relationship: Review the terms of the co-promotion agreement and the $40 million convertible debt, specifically the change-of-control provisions that could force a transfer of assets to King.
• Manufacturing Validation: Confirm the completion of validation for the new Philadelphia manufacturing facility to ensure commercial production can begin immediately upon approval.